North Growth Management Ltd. Has $11.68 Million Stock Holdings in InMode Ltd. (NASDAQ:INMD)

North Growth Management Ltd. lifted its holdings in InMode Ltd. (NASDAQ:INMD - Free Report) by 12.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 659,000 shares of the healthcare company's stock after purchasing an additional 75,000 shares during the quarter. InMode comprises 2.5% of North Growth Management Ltd.'s holdings, making the stock its 14th biggest position. North Growth Management Ltd. owned approximately 0.95% of InMode worth $11,683,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Raymond James Financial Inc. bought a new stake in InMode in the 4th quarter valued at approximately $1,332,000. Handelsbanken Fonder AB raised its holdings in shares of InMode by 34.3% in the first quarter. Handelsbanken Fonder AB now owns 36,400 shares of the healthcare company's stock valued at $646,000 after purchasing an additional 9,300 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of InMode by 13,923.8% in the first quarter. GAMMA Investing LLC now owns 2,945 shares of the healthcare company's stock worth $520,000 after purchasing an additional 2,924 shares in the last quarter. Townsquare Capital LLC lifted its position in shares of InMode by 43.2% in the fourth quarter. Townsquare Capital LLC now owns 17,029 shares of the healthcare company's stock worth $284,000 after purchasing an additional 5,137 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in InMode by 16.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 146,709 shares of the healthcare company's stock worth $2,450,000 after purchasing an additional 21,229 shares during the last quarter. 68.04% of the stock is owned by institutional investors.

InMode Trading Down 0.4%

Shares of INMD traded down $0.06 during midday trading on Friday, reaching $13.28. The stock had a trading volume of 1,103,251 shares, compared to its average volume of 1,189,473. The firm has a market cap of $839.43 million, a PE ratio of 5.70 and a beta of 1.98. The firm has a 50 day simple moving average of $14.51 and a 200-day simple moving average of $16.54. InMode Ltd. has a one year low of $13.16 and a one year high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last issued its earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.14). The firm had revenue of $77.87 million during the quarter, compared to analyst estimates of $82.21 million. InMode had a net margin of 44.79% and a return on equity of 17.17%. The company's revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter last year, the business posted $0.32 earnings per share. As a group, research analysts forecast that InMode Ltd. will post 1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on INMD. Robert W. Baird lowered shares of InMode from an "outperform" rating to a "neutral" rating and lowered their price target for the company from $22.00 to $16.00 in a research note on Monday, April 28th. Needham & Company LLC restated a "hold" rating on shares of InMode in a report on Monday, April 28th. Baird R W downgraded InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. UBS Group dropped their target price on InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. Finally, Barclays decreased their price target on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Seven equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $18.54.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.